Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 6/20 | 0.42 |
| ▸ | NOS3 | P29474 | 5/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7023474 | 0.83 | NOS2 (0.44) | NOS2NOS3NOS1PDE3BPDE3A | |
| SCHEMBL11489975 | 0.80 | NOS2 (0.56) | NOS2NOS3NOS1PDE3BPDE3A | |
| SCHEMBL1433191 | 0.80 | NOS2 (0.41) | NOS2NOS3NOS1PDE3BPDE3A | |
| SCHEMBL8416193 | 0.80 | NOS2 (0.41) | NOS2NOS3NOS1PDE3BPDE3A | |
| SCHEMBL21061316 | 0.80 | NOS2 (0.44) | NOS2NOS3NOS1PDE3BPDE3A | |
| SCHEMBL2555830 | 0.80 | NOS2 (0.48) | NOS2NOS3NOS1PDE3BPDE3A | |
| SCHEMBL28094709 | 0.78 | NOS2 (0.39) | NOS2NOS3NOS1PDE3BPDE3A | |
| SCHEMBL1966363 | 0.78 | NOS2 (0.39) | NOS2NOS3NOS1PDE3BPDE3A | |
| SCHEMBL31053616 | 0.78 | NOS2 (0.39) | NOS2NOS3NOS1PDE3BPDE3A | |
| SCHEMBL6968557 | 0.78 | NR4A2 (0.40) | NOS2NOS3NOS1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230105212-A1 | BIPHENYL DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-04-06 | — | — | US | disclosed |
| CN-104955824-B | It is used as the aminopyrimidine compounds of the inhibitor of the EGFR mutant containing T790M | 豪夫迈·罗氏有限公司 | 2017-09-22 | — | — | CN | disclosed |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| EP-1368342-B3 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORP (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2010-10-21 | — | — | US | disclosed |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| US-7642267-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090318472-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-24 | — | — | US | disclosed |
| CN-101611018-A | Heterocyclic sulfonamide with Edg-I antagonistic activity | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | CN | disclosed |
| US-7598251-B2 | Aminopyrazine derivatives and compositions | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2006-02-02 | — | — | US | disclosed |
| EP-1606266-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | disclosed |
| EP-1368342-B1 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6916827-B2 | Substituted ring-fused imidazole derivative: GABAA receptors ligands | NEUROGEN CORPORATION (US) | 2005-07-12 | — | — | US | disclosed |
| US-6916819-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2005-07-12 | — | — | US | disclosed |
| CN-1553909-A | Benzimidazole and pyridylimidazole derivatives as ligands for GABA receptors | — | 2004-12-08 | — | — | CN | disclosed |
| WO-2004084813-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040014780-A1 | Substituted ring-fused imidazole derivative: GABAA receptors ligands | NEUROGEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20030069257-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | NOS2 4108/4885NOS3 3877/4885NOS1 4528/4885 |
| US-20040014780-A1 | Substituted ring-fused imidazole derivative: GABAA receptors ligands | GABRB1, GABRA1, GABRB3 | NOS2 2644/4885NOS3 2271/4885NOS1 2667/4885 |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABBR2, GABRA2 | NOS2 4108/4885NOS3 3877/4885NOS1 4528/4885 |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | NOS2 614/4885NOS3 179/4885NOS1 481/4885 |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | EDF1, ERLIN1, ECE1 | NOS2 1380/4885NOS3 1565/4885NOS1 646/4885 |
| US-20230105212-A1 | BIPHENYL DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, TMBIM6, CYP46A1 | NOS2 2946/4885NOS3 3855/4885NOS1 2932/4885 |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | SGK1, SGK2, SGK3 | NOS2 2355/4885NOS3 1878/4885NOS1 1801/4885 |
| US-20030069257-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABRA1, GABBR2 | NOS2 4220/4885NOS3 3972/4885NOS1 4293/4885 |
| US-20090318472-A1 | AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS | STK25, ABL1, STK35 | NOS2 2019/4885NOS3 2305/4885NOS1 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.